气道压力释放通气与低潮气量通气在ARDS中的生理学比较:一项随机对照试验
这项单中心随机对照试验纳入40例中重度ARDS患者,随机接受气道压力释放通气(APRV)或低潮气量(LTV)通气,每组20例,用电阻抗断层成像(EIT)评估肺通气与灌注。24小时内,APRV组背侧通气变化中位数10.82% vs LTV组0.12%(P=0.017),背侧分流变化-4.67% vs 1.73%(P=0.008),背侧通气血流比匹配变化4.13% vs -3.29%(P=0.026);腹侧死腔无差异(P=0.903)。APRV组整体不均质性指数显著降低、通气中心显著升高,24小时PaO2/FiO2和呼吸系统静态顺应性更高、PaCO2更低,两组心输出量相当。
要点
- 中重度ARDS控制性通气患者随机接受APRV或LTV通气,每组20例,用EIT评估通气和灌注。
- 24小时内APRV组背侧通气变化中位数10.82% vs LTV组0.12%(P=0.017),背侧分流变化-4.67% vs 1.73%(P=0.008)。
- APRV组背侧通气血流比匹配变化4.13% vs LTV组-3.29%(P=0.026),腹侧死腔两组无差异(P=0.903)。
- APRV组整体不均质性指数显著降低、通气中心显著升高;24小时PaO2/FiO2和呼吸系统静态顺应性更高、PaCO2更低。
- 两组心输出量相当。
适用人群与场景
- 中重度ARDS并接受控制性机械通气的患者。
研究设计与关键结果
- 研究类型:单中心随机对照试验;共纳入40例中重度ARDS患者,随机分为APRV组或LTV通气组,每组20例。
- 评估方法:用电阻抗断层成像(EIT)评估肺通气与灌注,在随机化前(0小时)及随机化后12小时和24小时收集EIT数据和呼吸、血流动力学临床变量。
- 背侧通气变化(24小时减0小时):APRV组中位数10.82%(四分位距2.62%-13.74%)vs LTV组0.12%(四分位距-2.81%至4.76%),P=0.017。
- 背侧分流变化:APRV组中位数-4.67%(四分位距-6.83%至0.59%)vs LTV组1.73%(四分位距-0.95%至5.53%),P=0.008。
- 背侧通气血流比匹配变化:APRV组中位数4.13%(四分位距-0.26%至10.47%)vs LTV组-3.29%(四分位距-5.05%至2.81%),P=0.026。
- 腹侧死腔两组无差异(P=0.903)。
- 通气分布异质性指标:整体不均质性指数在APRV组较LTV组显著降低,通气中心在APRV组较LTV组显著升高。
- 24小时APRV组PaO2/FiO2更高、呼吸系统静态顺应性更高、PaCO2更低;两组心输出量相当。
证据类型、等级与局限
- 证据类型:单中心随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与LTV通气相比,APRV可复张背侧区域、减少背侧分流、增加背侧通气血流比匹配并改善肺通气均质性,从而在中重度ARDS患者中带来更好的气体交换和呼吸系统静态顺应性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The physiologic effects of different ventilation strategies on patients with ARDS need to be better understood.
RESEARCH QUESTION: In patients with ARDS receiving controlled mandatory ventilation, does airway pressure release ventilation (APRV) improve lung ventilation/perfusion (V˙/Q˙) matching and ventilation homogeneity compared with low tidal volume (LTV) ventilation?
STUDY DESIGN AND METHODS: This study was a single-center randomized controlled trial. Patients with moderate to severe ARDS were ventilated randomly with APRV or LTV ventilation. Electrical impedance tomography (EIT) was used to assess lung ventilation and perfusion. EIT-based data and clinical variables related to respiratory and hemodynamic conditions were collected shortly before randomization (0 hours) and at 12 and 24 hours after randomization.
RESULTS: A total of 40 patients were included and randomized to the APRV or LTV ventilation group (20 per group). During the 24-hour trial period, patients receiving APRV exhibited significantly increased dorsal ventilation (difference value [24 hours minus 0 hours]: median, 10.82% [interquartile range (IQR), 2.62%-13.74%] vs 0.12% [IQR, -2.81% to 4.76%]; P = .017), decreased dorsal shunt (median, -4.67% [IQR, -6.83% to 0.59%] vs 1.73% [IQR, -0.95% to 5.53%]; P = .008), and increased dorsal V˙/Q˙ matching (median, 4.13% [IQR, -0.26% to 10.47%] vs -3.29% [IQR, -5.05% to 2.81%]; P = .026) than those receiving LTV ventilation. No difference in ventral dead space was observed between study groups (P = .903). Additionally, two indicators of ventilation distribution heterogeneity, global inhomogeneity index and center of ventilation, significantly decreased and significantly increased, respectively, in the APRV group compared with the LTV ventilation group. Patients receiving APRV showed significantly higher Pao2 to Fio2 ratio, higher respiratory system static compliance and lower Paco2 than those receiving LTV ventilation at 24 hours. The cardiac output was comparable in both groups.
INTERPRETATION: APRV, as compared with LTV ventilation, could recruit dorsal region, reduce dorsal shunt, increase dorsal V˙/Q˙ matching, and improve ventilation homogeneity of the lungs, leading to better gas exchange and respiratory system static compliance in patients with moderate to severe ARDS.
CLINICAL TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT05767125; URL: www.
CLINICALTRIALS: gov.
参考来源
- Zou X, Zhang H, Wu Y, et al. Physiologic Comparison of Airway Pressure Release Ventilation and Low Tidal Volume Ventilation in ARDS: A Randomized Controlled Trial. Chest. 2024. PMID: 39299389. doi:10.1016/j.chest.2024.08.050
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。